The relationship between plasma psoralen concentration and psoralen‐UVA erythema

The plasma 8‐methoxypsoralen (8‐MOP) concentration was measured in 60 patients commencing psoralen photochemotherapy (PUVA). At the time of blood sampling each patient was phototested using a series of 10 exposures to UVA. The resulting erythema was measured objectively 72 h after irradiation and dose‐response curves for psoralen‐UVA erythema were constructed. Although the dose of 8‐MOP was calculated according to body weight, patients receiving 30 mg of 8‐MOP had a significantly lower mean plasma concentration than those receiving higher doses. There was no significant correlation between plasma 8‐MOP concentration and minimal phototoxic dose, either estimated visually or calculated from the dose‐response curves. However the slope of the dose‐response curve showed significant correlation with plasma 8‐MOP concentration. The variation between patients in the rate of increase of the erythemal response, but not the variation in threshold sensitivity, can be explained by differences in plasma psoralen concentration.

[1]  B. Diffey,et al.  PUVA treatment of psoriasis in the United Kingdom , 1991, The British journal of dermatology.

[2]  B. Diffey,et al.  A comparison of the dose-response relationship for psoralen-UVA erythema and UVB erythema. , 1989, Archives of dermatology.

[3]  J. Ct.  Self-reported skin type and reactivity to UVB, UVA and PUVA irradiation. , 1989 .

[4]  F. Gasparro,et al.  Rapid and sensitive analysis of 8-methoxypsoralen in plasma. , 1988, The Journal of investigative dermatology.

[5]  B. Diffey,et al.  The erythemal response of human skin to ultraviolet radiation , 1985, The British journal of dermatology.

[6]  B. Diffey,et al.  Quantitative studies on cutaneous erythema induced by ultraviolet radiation , 1984, The British journal of dermatology.

[7]  B. Diffey,et al.  A portable instrument for quantifying erythema induced by ultraviolet radiation , 1984, The British journal of dermatology.

[8]  F. Wolff,et al.  Intraindividual and Interindividual variability in 8‐methoxypsoralen kinetics and effect in psoriatic patients , 1983, Clinical pharmacology and therapeutics.

[9]  D. P. Goldstein,et al.  Minimal phototoxic doses and 8-MOP plasma levels in PUVA patients. , 1982, The Journal of investigative dermatology.

[10]  G. Plewig,et al.  8‐MOP plasma levels in PUVA problem cases with psoriasis , 1979, The British journal of dermatology.

[11]  M. Ehrnebo,et al.  Serum concentration and phototoxic effect of methoxsalen in patients with psoriasis , 1979, Clinical pharmacology and therapeutics.

[12]  H. Hönigsmann,et al.  Phototesting and dosimetry for photochemotherapy , 1977, The British journal of dermatology.

[13]  C. Jansén.  Self-reported skin type and reactivity to UVB, UVA and PUVA irradiation. , 1989, Photo-dermatology.

[14]  D. Carter,et al.  Plasma levels of 8-methoxypsoralen determined by high-pressure liquid chromatography in psoriatic patients ingesting drug from two manufacturers. , 1980, The Journal of investigative dermatology.